Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
10 September 2026
No Comments
AstraZeneca and Daiichi Sankyo’s Enhertu is the first and only HER2-directed medicine to improve